The 340B Drug Discount Program: Complexity, Challenges, and Change
A Whitepaper from IQVIA
Few would have predicted when the 340B program was launched in 1992 it would consume 11% ($67.4B) of total US pharmaceutical sales (2019 sales volume dollarized using WAC) and grow at five times the rate of the overall pharmaceutical market (IQVIA DDD Subnational Sales database, 2018-2019). But despite its substantial and growing impact on the gross-to-net of many brands, the program and its actual impact are not well understood due to its complexity. This article describes how the 340B program works, the challenges it creates when it doesn’t, how it’s evolving, and possible strategies to mitigate its impact on gross-to-net. To download, simply log in or register for an Informa Connect account below, which will give you access to all our exclusive premium content.
